Risk for Myopericarditis Minimal Following COVID-19 Vaccination
A study was conducted to determine the incidence of myopericarditis following COVID-19 vaccination compared with non-COVID-19 vaccination.
A study was conducted to determine the incidence of myopericarditis following COVID-19 vaccination compared with non-COVID-19 vaccination.
The American College of Cardiology has published guidelines for managing adult patients with cardiovascular sequelae after COVID-19 infection.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination seems safe for patients with prior history of myocarditis, with no evidence of recurrence.
Elizabeth Profita, MD, and Gerard J. Boyle, MD, FACC, discuss myocarditis in younger populations and how pediatric cardiologists should respond with treatment.
Most patients were male with median age of about 16 years; most common symptom was chest pain
Using the Mayo Clinic’s COVID-19 Vaccine Registry, researchers were able to measure the incidence of myocarditis after patients received COVID-19 mRNA vaccination.
Estimated incidence highest among males 16 to 29 years; second study shows highest standardized incidence ratio for males 16 to 19 years.
However, the long-term effects of myocarditis in children associated with COVID-19 vaccination are unknown.
A significant number of cases of post-COVID-19 myocarditis have been reported.
Because myocarditis has a high mortality rate and can be difficult to detect, the authors of a narrative review aimed to standardize the diagnostic and therapeutic protocols.